John Desjarlais

Company: Xencor

Job title: CSO

Seminars:

Maximizing Therapeutic Impact with CD20- and CD19-Targeted T Cell Engagers in Autoimmune Disease 9:30 am

Evaluating B cell expression in CD20 vs CD19 to weigh the risks and benefits Engineering Bispecific antibodies by selecting the most effective formats for autoimmune disease applications Tuning the potency and half-life of Bispecific antibodies to optimize their therapeutic indexRead more

day: Day Two

Panel Discussion: TCEs vs Cell Therapy: Comparing the Pros & Cons to Build Smarter Pipelines with the Right Modality for the Right Target 11:00 am

As T-cell engagers (TCEs) rapidly emerge from oncology into the autoimmune space, the field is facing a crucial inflection point: how do TCEs stack up against T-cell therapies in terms of specificity, efficacy, and durability? This panel brings together leading voices spanning TCE and cell therapy modalities to debate how these technologies co-exist, compete, or…Read more

day: Day One